Radiation-agent combinations for glioblastoma: challenges in drug development and future considerations

Charles A. Kunos; Evanthia Galanis; Jeffrey Buchsbaum; Qian Shi; Lewis C. Strauss; C. Norman Coleman; Mansoor M. Ahmed

doi:10.1007/s11060-017-2458-0

Radiation-agent combinations for glioblastoma: challenges in drug development and future considerations

Charles A. Kunos, Evanthia Galanis, Jeffrey Buchsbaum, Qian Shi, Lewis C. Strauss, C. Norman Coleman, Mansoor M. Ahmed

Research output: Contribution to journal › Review article › peer-review

Abstract

Glioblastoma is an aggressive disease characterized by moderate initial response rates to first-line radiation–chemotherapy intervention followed by low poor response rates to second-line intervention. This article discusses novel strategic platforms for the development of radiation–investigational agent combination clinical trials for primary and recurrent glioblastoma in a NCI-NCTN settings with simultaneous analysis of challenges in the drug development process.

Original language	English (US)
Pages (from-to)	551-557
Number of pages	7
Journal	Journal of neuro-oncology
Volume	134
Issue number	3
DOIs	https://doi.org/10.1007/s11060-017-2458-0
State	Published - Sep 1 2017

Keywords

Cancer discovery
Clinical cancer research
Clinical trials
Experimental chemotherapy
Precision medicine
Radiotherapy

ASJC Scopus subject areas

Oncology
Neurology
Clinical Neurology
Cancer Research

Access to Document

10.1007/s11060-017-2458-0

Cite this

@article{76fde00049d848cf92f7fa6cd6c4460a,

title = "Radiation-agent combinations for glioblastoma: challenges in drug development and future considerations",

abstract = "Glioblastoma is an aggressive disease characterized by moderate initial response rates to first-line radiation–chemotherapy intervention followed by low poor response rates to second-line intervention. This article discusses novel strategic platforms for the development of radiation–investigational agent combination clinical trials for primary and recurrent glioblastoma in a NCI-NCTN settings with simultaneous analysis of challenges in the drug development process.",

keywords = "Cancer discovery, Clinical cancer research, Clinical trials, Experimental chemotherapy, Precision medicine, Radiotherapy",

author = "Kunos, {Charles A.} and Evanthia Galanis and Jeffrey Buchsbaum and Qian Shi and Strauss, {Lewis C.} and Coleman, {C. Norman} and Ahmed, {Mansoor M.}",

note = "Publisher Copyright: {\textcopyright} 2017, Springer Science+Business Media New York (outside the USA).",

year = "2017",

month = sep,

day = "1",

doi = "10.1007/s11060-017-2458-0",

language = "English (US)",

volume = "134",

pages = "551--557",

journal = "Journal of neuro-oncology",

issn = "0167-594X",

publisher = "Kluwer Academic Publishers",

number = "3",

}

TY - JOUR

T1 - Radiation-agent combinations for glioblastoma

T2 - challenges in drug development and future considerations

AU - Kunos, Charles A.

AU - Galanis, Evanthia

AU - Buchsbaum, Jeffrey

AU - Shi, Qian

AU - Strauss, Lewis C.

AU - Coleman, C. Norman

AU - Ahmed, Mansoor M.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Glioblastoma is an aggressive disease characterized by moderate initial response rates to first-line radiation–chemotherapy intervention followed by low poor response rates to second-line intervention. This article discusses novel strategic platforms for the development of radiation–investigational agent combination clinical trials for primary and recurrent glioblastoma in a NCI-NCTN settings with simultaneous analysis of challenges in the drug development process.

AB - Glioblastoma is an aggressive disease characterized by moderate initial response rates to first-line radiation–chemotherapy intervention followed by low poor response rates to second-line intervention. This article discusses novel strategic platforms for the development of radiation–investigational agent combination clinical trials for primary and recurrent glioblastoma in a NCI-NCTN settings with simultaneous analysis of challenges in the drug development process.

KW - Cancer discovery

KW - Clinical cancer research

KW - Clinical trials

KW - Experimental chemotherapy

KW - Precision medicine

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=85019688888&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019688888&partnerID=8YFLogxK

U2 - 10.1007/s11060-017-2458-0

DO - 10.1007/s11060-017-2458-0

M3 - Review article

C2 - 28560665

AN - SCOPUS:85019688888

SN - 0167-594X

VL - 134

SP - 551

EP - 557

JO - Journal of neuro-oncology

JF - Journal of neuro-oncology

IS - 3

ER -

Radiation-agent combinations for glioblastoma: challenges in drug development and future considerations

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this